Building Optimal Three-Drug Combination Chemotherapy Regimens-Reference-Cited by-同舟云学术

Building Optimal Three-Drug Combination Chemotherapy Regimens

Published:2020-10-20 Issue:11 Volume:64 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Drusano G. L.¹,Neely Michael N.²,Kim Sarah³^ORCID,Yamada Walter M.²,Schmidt Stephan³,Duncanson Brandon¹,Nole Jocelyn¹,Mtchedlidze Nino¹,Peloquin Charles A.⁴^ORCID,Louie Arnold¹

Affiliation:

1. Institute for Therapeutic Innovation, College of Medicine, University of Florida, Orlando, Florida, USA

2. Division of Pediatric Infectious Diseases, Children’s Hospital of Los Angeles, Los Angeles, California, USA

3. Center for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, College of Pharmacy, University of Florida, Orlando, Florida, USA

4. Division Head for the Translational Research Division, Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, Florida, USA

Abstract

Multidrug therapy is often required. Examples include antiviral therapy, nosocomial infections, and, most commonly, anti- Mycobacterium tuberculosis therapy. Our laboratory previously identified a mathematical approach to identify 2-drug regimens with a synergistic or additive interaction using a full factorial study design. Our objective here was to generate a method to identify an optimal 3-drug therapy. We studied M. tuberculosis isolate H37Rv in log-phase growth in flasks.

Funder

HHS | NIH | National Institute of Allergy and Infectious Diseases

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01610-20

Reference27 articles.

1. Analysis of Combination Drug Therapy to Develop Regimens with Shortened Duration of Treatment for Tuberculosis

2. Combination Treatment With Meropenem Plus Levofloxacin Is Synergistic Against Pseudomonas aeruginosa Infection in a Murine Model of Pneumonia

3. Sofosbuvir (SOF) Suppresses Ledipasvir (LDV)-resistant Mutants during SOF/LDV Combination Therapy against Genotype 1b Hepatitis C Virus (HCV)